Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $17 to $14.
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $17 to $14.
